Skip to main content Accessibility help

Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr−/− mice

  • Donald B. Jump (a1), Christopher M. Depner (a1), Sasmita Tripathy (a1) and Kelli A. Lytle (a1)


The prevalence of non-alcoholic fatty liver disease (NAFLD) has increased in parallel with central obesity and is now the most common chronic liver disease in developed countries. NAFLD is defined as excessive accumulation of lipid in the liver, i.e. hepatosteatosis. The severity of NAFLD ranges from simple fatty liver (steatosis) to non-alcoholic steatohepatitis (NASH). Simple steatosis is relatively benign until it progresses to NASH, which is characterised by hepatic injury, inflammation, oxidative stress and fibrosis. Hepatic fibrosis is a risk factor for cirrhosis and primary hepatocellular carcinoma. Our studies have focused on the impact of diet on the onset and progression of NASH. We developed a mouse model of NASH by feeding Ldlr−/− mice a western diet (WD), a diet moderately high in saturated and trans-fat, sucrose and cholesterol. The WD induced a NASH phenotype in Ldlr−/− mice that recapitulates many of the clinical features of human NASH. We also assessed the capacity of the dietary n-3 PUFA, i.e. EPA (20 : 5,n-3) and DHA (22 : 6,n-3), to prevent WD-induced NASH in Ldlr−/− mice. Histologic, transcriptomic, lipidomic and metabolomic analyses established that DHA was equal or superior to EPA at attenuating WD-induced dyslipidemia and hepatic injury, inflammation, oxidative stress and fibrosis. Dietary n-3 PUFA, however, had no significant effect on WD-induced changes in body weight, body fat or blood glucose. These studies provide a molecular and metabolic basis for understanding the strengths and weaknesses of using dietary n-3 PUFA to prevent NASH in human subjects.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr−/− mice
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr−/− mice
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr−/− mice
      Available formats


Corresponding author

* Corresponding author: Professor D. B. Jump, fax 541-737-6914, email


Hide All
1. Centers for Disease Control (2015) Adult obesity facts. (accessed April 2015).
2. Centers for Disease Control (2015) Childhood obesity facts. (accessed April 2015).
3. Farrell, GC & Larter, CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99S112.
4. Cohen, JC, Horton, JD & Hobbs, HH (2011) Human fatty liver disease: old questions and new insights. Science 332, 15191523.
5. Bellentani, S, Scaglioni, F, Marino, M et al. (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28, 155161.
6. Angulo, P & Lindor, KD (2002) Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17, Suppl., S186S190.
7. Neuschwander-Tetri, BA & Caldwell, SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37, 12021219.
8. Kim, CH & Younossi, ZM (2008) Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 75, 721728.
9. Alberti, KG, Zimmet, P & Shaw, J (2005) The metabolic syndrome–a new worldwide definition. Lancet 366, 10591062.
10. Vernon, G, Baranova, A & Younossi, ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34, 274285.
11. Angulo, P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346, 12211231.
12. Chalasani, N, Younossi, Z, Lavine, JE et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 15921609.
13. McCullough, AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40, Suppl. 1, S17S29.
14. Prashanth, M, Ganesh, HK, Vima, MV et al. (2009) Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 57, 205210.
15. Soderberg, C, Stal, P, Askling, J et al. (2010) Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51, 595602.
16. Ekstedt, M, Franzen, LE, Mathiesen, UL et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865873.
17. Adams, LA, Lymp, JF, St Sauver, J et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113121.
18. McCullough, AJ (2004) The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8, 521533.
19. McCollough, AJ (2011) Epidemiology of the metabolic syndrome in the USA. J Dig Dis 12, 333340.
20. Leslie, M (2015) The liver's weight problem. Science 1820.
21. Day, CP & James, OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114, 842845.
22. LaBrecque, D, Abbas, Z, Anania, F et al. (2012) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. World Gastroenterol Org Global Guidelines 129.
23. Tilg, H & Moschen, AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 18361846.
24. Hashimoto, E, Tokushige, K & Farrell, GC (2011) Histological features of non-alcoholic fatty liver disease: what is important? J Gastroenterol Hepatol 27, 57.
25. Friedman, SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 16551669.
26. Abdelmalek, MF, Suzuki, A, Guy, C et al. (2010) Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 19611971.
27. Guturu, P & Duchini, A (2012) Etiopathogenesis of nonalcoholic steatohepatitis: role of obesity, insulin resistance and mechanisms of hepatotoxicity. Int J Hepatol 2012, 212865.
28. Wouters, K, van Gorp, PJ, Bieghs, V et al. (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474486.
29. Pagadala, M, Kasumov, T, McCullough, AJ et al. (2012) Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 23, 365371.
30. Harte, AL, da Silva, NF, Creely, SJ et al. (2010) Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflammation 7, 15. PubMed.
31. Hooper, AJ, Adams, LA & Burnett, JR (2011) Genetic determinants of hepatic steatosis in man. J Lipid Res 52, 593617.
32. Bieghs, V, Van Gorp, PJ, Wouters, K et al. (2012) LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS ONE 7, e30668.
33. Joyce, SA, MacSharry, J, Casey, PG et al. (2014) Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA 111, 74217426.
34. Elinav, E, Ali, M, Bruck, R et al. (2009) Competitive in hibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology 49, 278286.
35. Donnelly, KL, Smith, CI, Schwarzenberg, SJ et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 13431351.
36. Matherly, SC & Puri, P (2012) Mechanisms of simple hepatic steatosis: not so simple after all. Clin Liver Dis 16, 505524.
37. Toshimitsu, K, Matsuura, B, Ohkubo, I et al. (2007) Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 23, 4652.
38. Musso, G, Gambino, R, De Michieli, F et al. (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37, 909916.
39. Capanni, M, Calella, F, Biagini, MR et al. (2006) Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23, 11431151.
40. Cortez-Pinto, H, Jesus, L, Barros, H et al. (2006) How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 25, 816823.
41. Levy, JR, Clore, JN & Stevens, W (2004) Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 39, 608616.
42. Pachikian, BD, Essaghir, A, Demoulin, JB et al. . Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets. PLoS ONE 6, e23365.
43. Jump, DB, Tripathy, S & Depner, CM (2013) Fatty acid-regulated transcription factors in the liver. Annu Rev Nutr 33, 249269.
44. Zelber-Sagi, S, Ratziu, V & Oren, R (2011) Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 17, 33773389.
45. Tetri, LH, Basaranoglu, M, Brunt, EM et al. (2008) Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295, G987G995.
46. Lottenberg, AM, Afonso Mda, S, Lavrador, MS et al. (2012) The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem 23, 10271040.
47. Wouters, K, van Bilsen, M, van Gorp, PJ et al. (2010) Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 584, 10011005.
48. Teratani, T, Tomita, K, Suzuki, T et al. (2012) A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142, 152164 e10.
49. Depner, CM, Torres-Gonzalez, M, Tripathy, S et al. (2012) Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/- mice. J Nutr 142, 14951503.
50. Yasutake, K, Nakamuta, M, Shima, Y et al. (2009) Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 44, 471477.
51. Walenbergh, SMA, Koek, GH, Bieghs, V et al. (2013) Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol 58, 801820.
52. Marriott, BP, Olsho, L, Hadden, L et al. (2010) Intake of added sugars in the United States: what is the measure? Am J Clin Nutr 94, 16521653.
53. Chun, OK, Chung, CE, Wang, Y et al. (2010) Changes in intakes of total and added sugar and their contribution to energy intake in the U.S. Nutrients 2, 834854.
54. Chanmugam, P, Guthrie, JF, Cecilio, S et al. (2003) Did fat intake in the United States really decline between 1989–1991 and 1994–1996? J Am Diet Assoc 103, 867872.
55. Lee, S, Harnack, L, Jacobs, DR Jr et al. (2007) Trends in diet quality for coronary heart disease prevention between 1980–1982 and 2000–2002: the Minnesota Heart Survey. J Am Diet Assoc 107, 213222.
56. Marriott, BP, Olsho, L, Hadden, L et al. (2010) Intake of added sugars and selected nutrients in the United States, National Health and Nutrition Examination Survey (NHANES) 2003–2006. Crit Rev Food Sci Nutr 50, 228258.
57. Vos, MB, Kimmons, JE, Gillespie, C et al. (2008) Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med 10, 160.
58. Lim, JS, Mietus-Snyder, M, Valente, A et al. (2010) The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7, 251264.
59. Bizeau, ME & Pagliassotti, MJ (2005) Hepatic adaptations to sucrose and fructose. Metabolism 54, 11891201.
60. Leclercq, IA, Field, J, Enriquez, A et al. (2000) Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem Biophys Res Commun 268, 337344.
61. Schalkwijk, CG, Stehouwer, CD & van Hinsbergh, VW (2004) Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 20, 369382.
62. Bunn, HF & Higgins, PJ (1981) Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213, 222224.
63. Bose, T & Chakraborti, AS (2008) Fructose-induced structural and functional modifications of hemoglobin: implication for oxidative stress in diabetes mellitus. Biochim Biophys Acta 1780, 800808.
64. Wei, Y, Wang, D, Moran, G et al. (2013) Fructose-induced stress signaling in the liver involves methylglyoxal. Nutr Meta (Lond) 10, 3238.
65. Chan, HL, de Silva, HJ, Leung, NW et al. (2007) How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol 22, 801808.
66. Musso, G, Cassader, M, Rosina, F et al. (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885904.
67. Petit, JM, Guiu, B, Duvillard, L et al. (2012) Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. Clin Nutr 31, 520525.
68. Zheng, JS, Xu, A, Huang, T et al. (2012) Low docosahexaenoic acid content in plasma phospholipids is associated with increased non-alcoholic fatty liver disease in China. Lipids 47, 549556.
69. Parker, HM, Johnson, NA, Burdon, CA et al. (2012) Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56, 944951.
70. Di Minno, MN, Russolillo, A, Lupoli, R et al. (2012) Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 18, 58395847.
71. Nobili, V, Bedogni, G, Alisi, A et al. (2011) Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96, 350353.
72. Shapiro, H, Tehilla, M, Attal-Singer, J et al. (2011) The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr 30, 619.
73. Cohen-Naftaly, M & Friedman, SL (2011) Current status of novel antifibrotic thearpies in patients with chronic liver disease. Ther Adv Gastroenterol 4, 391417.
74. Schuppan, D & Kim, YO (2013) Evolving therapies for liver fibrosis. J Clin Invest 123, 18871901.
75. Wang, Y, Botolin, D, Christian, B et al. (2005) Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases. J Lipid Res 46, 706715.
76. Tripathy, S, Torres-Gonzalez, M & Jump, DB (2010) Elevated hepatic fatty acid elongase-5 activity corrects dietary fat-induced hyperglycemia in obese C57BL/6J mice. J Lipid Res 51, 26422654.
77. Depner, CM, Philbrick, KA & Jump, DB (2013) Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. J Nutr 143, 315323.
78. Depner, CM, Traber, MG, Bobe G et al. (2013) A metabolomic analysis of omega-3 fatty acid mediated attenuation of western diet-induced non-alcoholic steatohepatitis in LDLR-/- mice. Plos ONE 8, e83756.
79. Tripathy, S & Jump, DB (2013) Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-Vaccenic acid synthesis in diet-induced obese mice. J Lipid Res 54, 7184.
80. Tripathy, S, Lytle, KA, Stevens, RD et al. (2014) Fatty acid elongase-5 (Elovl5) regulates hepatic triglyceride catabolism in obese C57BL/6J mice. J Lipid Res 55, 14481464.
81. Saraswathi, V, Gao, L, Morrow, JD et al. (2007) Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. J Nutr 137, 17761782.
82. Ganz, M, Bukong, TN, Csak, T et al. (2015) Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med 13, 193207.
83. Charlton, M, Krishnan, A, Viker, K et al. (2011) Fast food diet mouse: novel small animal model of NASH with balloning, progressive fibrosis and high physiological facelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301, G825GG34.
84. Cordain, L, Eaton, SB, Sebastian, A et al. (2005) Orgins and evolution of the western diet: health implications for the 21st century. Am J Clin Nutr 81, 341354.
85. Ishimoto, T, Lanaspa, MA, Rivard, CJ et al. (2013) High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 58, 16321643.
86. Arendt, BM, Comelli, EM, Ma, DW et al. (2015) Altered hepatic gene expression in non-alcoholic fatty liver disease is associated with lower n-3 and n-6 polyunsaturated fatty acids. Hepatology 61, 15651578.
87. Lee, JJ, Lambert, JE, Hovhannisyan, Y et al. (2015) Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr 101, 3443.
88. Sofi, F, Giangrandi, I, Cesari, F et al. (2011) Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 61, 792802.
89. Bulchandani, DG, Nachnani, JS, Nookala, A et al. (2011) Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis. Eur J Gastroenterol Hepatol 22, 12451252.
90. Ishikawa, Y, Yokoyama, M, Saito, Y et al. (2011) Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J 74, 14511457.
91. Kishino, T, Ohnishi, H, Ohtsuka, K et al. (2011) Low concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injury. Clin Chem Lab Med 49, 159162.
92. Scorletti, E, Bhatia, L, McCormick, KG et al. (2014) Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the *WELCOME study. Hepatology 60, 12111221.
93. Kadiiska, MB, Gladen, BC, Baird, DD et al. (2005) Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 38, 698710.
94. US National Institute of health (2015) NAFLD, NASH and omega-3 fatty acids. (accessed April 2015).
95. Barter, P & Ginsberg, HN (2008) Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 102, 10401045.
96. Superko, HR, Superko, SM, Nasir, K et al. (2013) Omega-3 fatty acid blood levels. Clinical significance and controversy. Circulation 128, 21542161.
97. Lockyer, S, Tzanetou, M, Carvalho-Wells, AL et al. (2012) STAT gene dietary model to implement diets of differing fat composition in prospectively genotyped groups (apoE) using commercially available foods. Br J Nutr 108, 17051713.
98. Di Stasi, D, Bernasconi, R, Marchioli, R et al. (2004) Early modification of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 PUFA. Eur J Clin Pharmacol 60, 183190.
99. Cani, PD, Amar, J, Iglesias, MA et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 17611772.
100. Leclercq, IA, Farrell, GC, Schriemer, R et al. (2002) Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37, 206213.
101. Marra, F, Gastaldelli, A, Baroni, GS et al. (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14, 7281.
102. Akira, S & Takeda, K (2004) Toll-like receptor signalling. Nat Rev Immunol 4, 499511.
103. Erridge, C, Attina, T, Spickett, CM et al. (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86, 12861292.
104. Laugerette, F, Vors, C, Geloen, A et al. (2011) Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutritional Biochem 22, 5359.
105. Goel, A, Gupta, M & Aggarwal, R (2014) Gut microbiota and liver disease. J Gastroenterol Hepatol 29, 11391148.
106. Henao-Mejia, J, Elinav, E, Jin, C et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179185.
107. Adinolfi, LE & Restivo, L (2011) Does vitamin E cure nonalcoholic steatohepatitis? Expert Rev Gastroenterol Hepatol 5, 147150.
108. Brenner, DA, Seki, E, Taura, K et al. (2011) Non-alcoholic steatohepatitis-induced fibrosis: toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res 41, 683686.
109. Bi, P & Kuang, S (2015) Notch signaling as a novel regulator of metabolism. Trends Endocrinol Metabol 26, 248255.


Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr−/− mice

  • Donald B. Jump (a1), Christopher M. Depner (a1), Sasmita Tripathy (a1) and Kelli A. Lytle (a1)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed